ℹ️
🇬🇧
Search
Search for people relevant for "Short-chain dehydrogenases/reductases"
Short-chain dehydrogenases/reductases
Person
Class
Person
Publication
Programmes
Export current view
doc. RNDr. Jakub Hofman Ph.D.
Academic staff at Faculty of Pharmacy in Hradec Králové
3 classes
37 publications
Classes
class
Current Strategies in Pharmacotherapy
GAF360 |
Faculty of Pharmacy in Hradec Králové
class
Current strategies in pharmacotherapy
+1
GAPS016 |
Faculty of Pharmacy in Hradec Králové
Publications
publication
Buparlisib is a novel inhibitor of daunorubicin reduction mediated by aldo-keto reductase 1C3
2019 |
Faculty of Pharmacy in Hradec Králové
publication
Roscovitine and purvalanol A effectively reverse anthracycline resistance mediated by the activity of aldo-keto reductase 1C3 (AKR1C3): A promising therapeutic target for cancer treatment
2018 |
Faculty of Pharmacy in Hradec Králové
publication
Inhibition of human anthracycline reductases by emodin - A possible remedy for anthracycline resistance
2016 |
Faculty of Pharmacy in Hradec Králové
publication
Tazemetostat synergistically combats multidrug resistance by the unique triple inhibition of ABCB1, ABCC1, and ABCG2 efflux transporters in vitro and ex vivo
2023 |
Faculty of Pharmacy in Hradec Králové, Faculty of Medicine in Hradec Králové
publication
Sonidegib potentiates the cancer cells' sensitivity to cytostatic agents by functional inhibition of ABCB1 and ABCG2 in vitro and ex vivo
2022 |
Faculty of Pharmacy in Hradec Králové, Faculty of Medicine in Hradec Králové
publication
Talazoparib Does Not Interact with ABCB1 Transporter or Cytochrome P450s, but Modulates Multidrug Resistance Mediated by ABCC1 and ABCG2: An in Vitro and Ex Vivo Study
2022 |
Faculty of Pharmacy in Hradec Králové, Faculty of Medicine in Hradec Králové
publication
Encorafenib Acts as a Dual-Activity Chemosensitizer through Its Inhibitory Effect on ABCC1 Transporter In Vitro and Ex Vivo
2022 |
Faculty of Pharmacy in Hradec Králové, Faculty of Medicine in Hradec Králové
publication
Dabrafenib inhibits ABCG2 and cytochrome P450 isoenzymes; potential implications for combination anticancer therapy
2022 |
Faculty of Pharmacy in Hradec Králové
publication
Alisertib shows negligible potential for perpetrating pharmacokinetic drug-drug interactions on ABCB1, ABCG2 and cytochromes P450, but acts as dual-activity resistance modulator through the inhibition of ABCC1 transporter
2022 |
Faculty of Pharmacy in Hradec Králové
publication
Bruton's Tyrosine Kinase Inhibitor Zanubrutinib Effectively Modulates Cancer Resistance by Inhibiting Anthracycline Metabolism and Efflux
2022 |
Faculty of Pharmacy in Hradec Králové
Load more publications (27)
Loading network view...